Journal of Immunotherapy最新文献

Integrated Genomic Analysis Identifies Clinically Relevant Molecular Subtypes and Disulfidptosis-Related Prognostic Signature of Gastric Cancer. 综合基因组分析鉴定胃癌临床相关分子亚型和双歧杆菌相关预后特征

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-07-14 DOI: 10.1097/CJI.0000000000000570

Yatao Wang, Fengqin Guo, Wei Song, Yanliang Liu, Qijun Xiang

{"title":"Integrated Genomic Analysis Identifies Clinically Relevant Molecular Subtypes and Disulfidptosis-Related Prognostic Signature of Gastric Cancer.","authors":"Yatao Wang, Fengqin Guo, Wei Song, Yanliang Liu, Qijun Xiang","doi":"10.1097/CJI.0000000000000570","DOIUrl":"10.1097/CJI.0000000000000570","url":null,"abstract":"Disulfidptosis is a newly defined disulfide stress-induced cell death. However, there are gaps in the prognostic role of disulfidptosis-related genes (DRGs) and their correlation with the tumor microenvironment (TME) in gastric cancer (GC). In here, we systematically investigated DRG changes at genomic and transcriptional levels, prognostic value, and their expression patterns in GC. Fifteen DRGs were used to identify the different subtypes, and the differences in prognosis and immune infiltration among the subtypes were examined. We identified 3 distinct molecular subtypes and observed profound differences among the 3 subtypes in clinical outcomes and infiltrating immune cells. Subsequently, a disulfidptosis-related signature (DRG_score) was constructed based on the overlapped disulfidptosis phenotype-related differentially expressed genes and was verified in an external cohort. The multivariate analysis confirmed that the DRG_score serves as an independent prognostic indicator for GC, and then a nomogram was built to increase the clinical applicability of the DRG_score. Furthermore, significant variations were observed in the TME, expression of multiple immune checkpoints, microsatellite status, tumor mutational burden, and response to different chemotherapeutics among the 2 DRG_score groups. A low DRG_score implies more significant TME cell infiltration and better response to immunotherapy. In conclusion, we present a comprehensive overview of the DRG profile in GC and develop a novel signature for GC patients. These findings could help us better understand DRG in GC and provide a theoretical foundation for future studies targeting disulfidptosis in GC.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"343-357"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling. 通过三维数学模型评估抗pd - l1治疗和CD8+ t细胞激活纳米治疗在胰腺导管腺癌中的协同作用。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-07-18 DOI: 10.1097/CJI.0000000000000572

Dylan A Goodin, Tina Daunke, Silje Beckinger, Sandra Krüger, Christoph Röcken, Susanne Sebens, Hermann B Frieboes

{"title":"Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling.","authors":"Dylan A Goodin, Tina Daunke, Silje Beckinger, Sandra Krüger, Christoph Röcken, Susanne Sebens, Hermann B Frieboes","doi":"10.1097/CJI.0000000000000572","DOIUrl":"10.1097/CJI.0000000000000572","url":null,"abstract":"Summary: Although targeting programmed cell death ligand 1 (PD-L1) has been ineffective in reducing pancreatic ductal adenocarcinoma (PDAC) burden in preclinical and clinical studies, it is unknown if increasing activated CD8+ T-cell numbers, independently or in combination with anti-PD-L1 therapeutics, would improve tumor response. To facilitate evaluation of novel combinatorial strategies targeting PDAC, this study developed a modeling framework to assess therapies targeting PD-L1 and T-cell activation. Chitosan nanoparticles (CNP) loaded with a model antigen have recently shown promising anti-tumor effects by increasing dendritic cell (DC) mediated T-cell activation in a murine PDAC model. Using these in vivo data, along with in vitro and primary and liver metastatic PDAC in situ data, a 3D continuum mixture model of PDAC was rigorously calibrated and solved through distributed computing. The model was applied to analyze the response to anti-PD-L1 and/or antigen-CNP therapies at primary and liver metastatic sites. The results show realistic evaluation of combination therapy targeting PDAC at primary and liver metastatic sites. With the given parameter set, the model projects that anti-PD-L1 therapy and antigen-CNP would synergistically decrease tumor burden at primary and liver metastatic sites to 53.2% and 58.4% of initial burden 5.0 and 5.2 days post-treatment initiation, respectively. Delaying antigen-CNP application 3 or 5 days after anti-PD-L1 and gemcitabine administration further limited metastatic PDAC to <50% of initial burden 15 days post-treatment initiation. In conclusion, the proposed modeling approach enables realistic evaluation of novel combinations of agents, with the goal to design improved PDAC therapy.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"331-342"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Efficacy and Safety of Cadonilimab Immunotherapy in Advanced Cervical Cancer: A Retrospective Study. 卡多尼单抗免疫治疗晚期宫颈癌的临床疗效和安全性：一项回顾性研究。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-08-21 DOI: 10.1097/CJI.0000000000000574

Xiuchen Han, Minjie Fang, Huaming Tan, Minjie Wang, Yayan Zhou, Xiugui Sheng

{"title":"Clinical Efficacy and Safety of Cadonilimab Immunotherapy in Advanced Cervical Cancer: A Retrospective Study.","authors":"Xiuchen Han, Minjie Fang, Huaming Tan, Minjie Wang, Yayan Zhou, Xiugui Sheng","doi":"10.1097/CJI.0000000000000574","DOIUrl":"10.1097/CJI.0000000000000574","url":null,"abstract":"This multicenter retrospective study assessed the safety and antitumor activity of cadonilimab in patients with recurrent or metastatic cervical cancer, particularly those with negative PD-L1 expression. Patients received cadonilimab, with or without additional treatments like chemotherapy, bevacizumab, or radiotherapy, and were monitored every 3 weeks until disease progression or intolerable toxicity was observed. The study included 21 patients: 18 with recurrent/metastatic cervical cancer (Figo IB1-IIIC) and 3 with newly diagnosed advanced cervical cancer (Fig IVB). The median follow-up duration was 9.7 (IQR: 2.3-23.6) months, and the median number of treatment cycles for cadonilimab was 10. Six patients had PD-L1-positive expression, and 6 had PD-L1-negative expression. Two patients with newly diagnosed advanced cervical cancer and 3 with recurrent disease achieved complete response; 10 patients had a partial response, and 1 patient had stable disease. Objective response rates were 71.4% (15 of 21 patients) overall and 66.7% (4 of 6 patients) for patients with PD-L1-negative expression. Grade 3-4 treatment-related adverse events occurred in 33.3% of patients, while immune-related adverse events were all G1-2 and occurred in 2 (9.5%) patients. No patients discontinued treatment due to intolerable toxicities. The study concluded that cadonilimab-containing therapies showed promising results in terms of responses and survival outcomes, with a favorable safety profile.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"358-364"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated Analysis of Single-cell and Bulk RNA-Sequencing Identifies a Signature Based on Cancer-related Fibroblast Marker Genes to Predict Prognosis and Therapy Response in Lung Adenocarcinoma. 单细胞和整体rna测序的综合分析确定了基于癌症相关成纤维细胞标记基因的特征，以预测肺腺癌的预后和治疗反应。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-08-20 DOI: 10.1097/CJI.0000000000000577

Gengqiu Liu, Jiacheng Feng, Yufeng Huang, Junhang Zhang, Yong Li

{"title":"Integrated Analysis of Single-cell and Bulk RNA-Sequencing Identifies a Signature Based on Cancer-related Fibroblast Marker Genes to Predict Prognosis and Therapy Response in Lung Adenocarcinoma.","authors":"Gengqiu Liu, Jiacheng Feng, Yufeng Huang, Junhang Zhang, Yong Li","doi":"10.1097/CJI.0000000000000577","DOIUrl":"10.1097/CJI.0000000000000577","url":null,"abstract":"Cancer-related fibroblasts (CAFs), crucial in the tumor microenvironment, significantly influence tumorigenesis and extracellular matrix shaping. This study aimed to analyze the expression of CAF marker genes in lung adenocarcinoma (LUAD) and create a prognostic signature. We included 716 LUAD patients from different cohorts, conducting a comprehensive analysis of single-cell RNA sequencing data from the Gene Expression Omnibus (GEO) database, identifying 227 CAF marker genes. Using the Cancer Genome Atlas (TCGA) LUAD cohort, we developed a 3-gene prognostic signature, categorizing patients into high-risk and low-risk groups. The signature's predictive capability was validated across clinical subgroups and GEO cohorts. It was determined as an independent prognostic factor via univariate and multivariate analyses, leading to the construction of a nomogram for clinical prognosis prediction. Immune profile analysis indicated that high-risk patients exhibited immunosuppression and immune cell infiltration, while the tumor immune dysfunction and exclusion score suggested higher immunotherapy sensitivity in the low-risk group. In addition, high-risk patients showed greater sensitivity to several first-line chemotherapeutic drugs. The expression of hub genes was validated using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and the Human Protein Atlas (HPA). In conclusion, this study presented a novel prognostic signature for LUAD patients based on CAF marker genes, demonstrating strong predictive power for prognosis and treatment response.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"365-378"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion. 阿特唑单抗和贝伐单抗在既往b细胞耗尽后完全缓解肝细胞癌。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-10-20 DOI: 10.1097/CJI.0000000000000583

Jen-Pei Huang, Chun-Kuang Tsai, Pei-Ying Hsieh, San-Chi Chen

{"title":"Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion.","authors":"Jen-Pei Huang, Chun-Kuang Tsai, Pei-Ying Hsieh, San-Chi Chen","doi":"10.1097/CJI.0000000000000583","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000583","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) are established therapies for unresectable hepatocellular carcinoma (HCC), with atezolizumab/bevacizumab and durvalumab/tremelimumab demonstrating clinical efficacy. Beyond activating CD8+ T cells, anti-PD(L)-1 therapies stimulate humoral immunity through B-cell activation and tertiary lymphoid structures. However, ICIs can also cause immune-related adverse events (irAEs), some managed with anti-CD20 therapy, raising concerns about whether B-cell depletion impacts subsequent ICI efficacy. This report presents a novel case of dual malignancies-diffuse large B-cell lymphoma (DLBCL) and HCC-in a patient in their 70s successfully treated with sequential R-CHOP and atezolizumab/bevacizumab. Following 6 cycles of R-CHOP for DLBCL, the patient achieved a complete metabolic response but developed recurrent HCC. Flow cytometry revealed B-cell depletion and hypogammaglobulinemia after R-CHOP. Upon initiation of atezolizumab/bevacizumab, AFP levels rapidly declined, and complete tumor remission was confirmed. Notably, NK cell percentages increased following ICI therapy, suggesting enhanced immune activation. This case demonstrates that prior rituximab-induced B-cell depletion does not impair the efficacy of anti-PD-L1 therapy in HCC and highlights the potential role of NK cells in mediating antitumor immunity during immunotherapy.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic and Epitranscriptomic Modulation by STAT1: Unraveling T Helper Cell Differentiation in NSCLC. STAT1的表观遗传和表转录组调控：揭示非小细胞肺癌中辅助性T细胞的分化。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-10-14 DOI: 10.1097/CJI.0000000000000582

Roshni Bibi, Melvin George, Koustav Sarkar

{"title":"Epigenetic and Epitranscriptomic Modulation by STAT1: Unraveling T Helper Cell Differentiation in NSCLC.","authors":"Roshni Bibi, Melvin George, Koustav Sarkar","doi":"10.1097/CJI.0000000000000582","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000582","url":null,"abstract":"Summary: The lack of targetable mutations in 50% of NSCLC cases and resistance to therapies underscore the need for alternative treatments, with epigenetic strategies potentially regulating tumor suppressor genes to inhibit growth. Our focus is to understand the STAT1-mediated epigenetic and epitranscriptomic modulations, such as R-loop formation, histone methylation/demethylation, histone acetylation and deacetylation, DNA methylation, and m6A RNA methylation, in T helper cell (TH) differentiation to evoke tumor-protective immune responses in non-small cell lung cancer (NSCLC) by knocking out (KO) and overexpressing (OE) STAT1. Peripheral blood mononuclear cells (PBMCs) were isolated from NSCLC patients and healthy controls using Ficoll-Hypaque density-gradient centrifugation. CD4+ T cells were purified with magnetic activated cell sorting (MACS). Subsequently, CRISPR/Cas9 knock-out and overexpression techniques were applied, followed by qRT-PCR to evaluate 5-mC, m6A RNA methylation, gene expression, and transcription factor enrichment. Mutations in STAT1 can cause severe immunodeficiency and malignancy, linked to genomic instability from R-loops-DNA-RNA hybrids that lead to DNA breaks through transcription-coupled nucleotide excision repair. Our study examines epigenetic regulators in CD4+ T helper cells from NSCLC patients, focusing on the effects of STAT1 depletion and overexpression on R-loop formation at key gene loci specific to T helper cells. Depletion of STAT1 increased R-loop frequencies, DNA methylation, histone deacetylation, and histone methylation, whereas its overexpression decreased them. Abnormal epitranscriptomic alterations, including m6A RNA methylation, were observed, indicating that STAT1 is crucial for T helper cell differentiation and immune responses in NSCLC, presenting promising avenues for targeted therapeutic interventions.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145286278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune Checkpoint Inhibitor-Induced Ureteritis and Cystitis in Patients With Lung Cancer and Uterine Malignancies: A Case Series and Literature Review. 免疫检查点抑制剂诱导的肺癌和子宫恶性肿瘤患者输尿管炎和膀胱炎：病例系列和文献综述

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-10-02 DOI: 10.1097/CJI.0000000000000581

Yu Yan, Qiqi Dou, Xuefei Wu, Xiaotong Zhang, Xiaoyan Liu, Xiaoyan Si, Li Zhang

{"title":"Immune Checkpoint Inhibitor-Induced Ureteritis and Cystitis in Patients With Lung Cancer and Uterine Malignancies: A Case Series and Literature Review.","authors":"Yu Yan, Qiqi Dou, Xuefei Wu, Xiaotong Zhang, Xiaoyan Liu, Xiaoyan Si, Li Zhang","doi":"10.1097/CJI.0000000000000581","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000581","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy across various cancers but can cause immune-related adverse events (irAEs). While common irAEs such as dermatitis, pneumonitis, and colitis are well-documented, rare events like cystitis and ureteritis remain underrecognized. We report 3 cases of ICI-induced cystitis and ureteritis. The first case involves a 67-year-old female with lung cancer who developed immune-related cystitis and ureteritis after 3 cycles of pembrolizumab, with recurrence 8 months after discontinuation. Both episodes presented with hematuria, urinary frequency, and dysuria, and were responsive to corticosteroid treatment. The second case involves a 37-year-old female with cervical cancer who developed a truncal rash, hematuria, urinary frequency, and dysuria after the first cycle of cadonilimab, a PD-1/CTLA-4 bispecific antibody. Her condition worsened with rising serum creatinine levels. Imaging revealed bladder wall thickening and ureteral dilation. Partial symptom relief followed oral corticosteroids, but complete resolution was achieved with intravesical corticosteroid irrigation. The third case describes a 35-year-old female with endometrial cancer who presented with similar urinary symptoms and flank pain after 4 cycles of pembrolizumab. Rapid creatinine elevation necessitated ureteral stent placement, which failed to alleviate symptoms. After exclusion of infectious etiologies, immune-related cystitis/ureteritis was diagnosed. Symptoms resolved with intravenous corticosteroids. This report underscores the importance of early recognition and management of rare urinary irAEs to avoid unnecessary interventions and prolonged interruption of anti-tumor therapy. It also highlights intravesical methylprednisolone as a potential treatment modality that warrants further investigation.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of Molecular Subtypes and a Novel Prognostic Model for Lung Squamous Cell Carcinoma Based on Adenylate Uridylate (AU)-Rich Element Genes. 基于富腺苷酸-尿苷酸（AU）元素基因的肺鳞癌分子亚型鉴定和新预后模型

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-23 DOI: 10.1097/CJI.0000000000000580

Junchao Huang, Siyang Chen, Yakun Liu

{"title":"Identification of Molecular Subtypes and a Novel Prognostic Model for Lung Squamous Cell Carcinoma Based on Adenylate Uridylate (AU)-Rich Element Genes.","authors":"Junchao Huang, Siyang Chen, Yakun Liu","doi":"10.1097/CJI.0000000000000580","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000580","url":null,"abstract":"Adenylate uridylate-rich element genes (AREGs) are crucial in modulating gene expression following transcription. However, the comprehensive role of AREGs in lung squamous carcinoma (LUSC) remains inadequately understood. Transcriptome data from TCGA and GTEx databases to identify differentially expressed AREGs. Clustering algorithms were used to identify AREGs-related subtypes, and a prognostic model was developed through univariate/multivariate and LASSO regression analyses. Following this, we created a nomogram integrating clinical pathologic characteristics and the risk model. The immune microenvironment was evaluated using CIBERSORT, ESTIMATE, and MCPcounter analyses. We examined the mRNA expression of the signature genes in normal and lung squamous carcinoma cells using RT-qPCR. Finally, we assessed the sensitivity to drugs based on the signature genes in risk patients. Patients with the 2 identified molecular subtypes exhibit distinct prognoses and immune microenvironments. We identified 5 genes with prognostic significance that can serve as independent predictors in clinical practice. The low-risk patients demonstrates more favorable prognostic outcomes, while the high-risk patients show elevated immune scores and increased immune cell infiltration, suggesting a favorable response to immunotherapy. RT-qPCR results showed upregulation of FAM83A and TINAGL1 and downregulation of FGG and ADH1C in LUSC. In addition, the low-risk patients show increased sensitivity to vinorelbine. The molecular subtypes and prognostic model based on AREGs demonstrate reliable clinical prognostic value. This finding may contribute to personalized and precise treatment for patients with LUSC, offering new insights for improving patient outcomes.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Administration of Cetuximab-Based Regimen as a Second Line After Pembrolizumab Among Incurable Head and Neck Squamous Cell Carcinoma Patients. 在无法治愈的头颈部鳞状细胞癌患者中，基于西妥昔单抗的方案作为派姆单抗后的二线治疗。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-17 DOI: 10.1097/CJI.0000000000000579

Noga Kurman, Ido Even-Tov, Ofir Zavdy, Eyal Yosefof

{"title":"The Administration of Cetuximab-Based Regimen as a Second Line After Pembrolizumab Among Incurable Head and Neck Squamous Cell Carcinoma Patients.","authors":"Noga Kurman, Ido Even-Tov, Ofir Zavdy, Eyal Yosefof","doi":"10.1097/CJI.0000000000000579","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000579","url":null,"abstract":"Summary: In the last years, combination of Pembrolizumab and chemotherapy has become standard of care first-line treatment among advanced-stage or metastatic head and neck squamous cell carcinoma (HNSCC) patients. However, the response rate for this treatment is still low, and most patients eventually progress, creating an unmet need for a standard second-line treatment. We aim to describe our experience with HNSCC patients who progress on Pembrolizumab and are treated with Cetuximab with or without chemotherapy. We performed a retrospective review of HNSCC patients who experienced disease progression after Pembrolizumab therapy (with or without chemotherapy) and subsequently received Cetuximab-containing regimens as second-line treatment, at a university-affiliated tertiary care center between 2019 and 2023. The study cohort comprised 21 patients whose disease progressed after a Pembrolizumab-containing first-line regimen. (mean age at HNSCC diagnosis: 66.3±13.2 y). Primary sites of origin were predominantly the oral cavity (52.4%, n=11) and oropharynx (19%, n=4). Treatment outcomes were as follows: complete response (14.3%, n=3), partial response (38.1%, n=8), stable disease (19.1%, n=4), and progression of disease (28.6%, n=6). The overall response rate was 52.4%, with a disease control rate of 71.4%. Median progression-free survival was 7.3 months (range: 1-38.3 mo). Cetuximab-containing second-line regimens demonstrated promising efficacy in HNSCC patients who progressed on Pembrolizumab-based protocols, yielding favorable response rates and durable responses. These findings warrant further investigation through prospective clinical trials to establish consensus guidelines for this patient population.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab Induced Aortitis in a Patient With Head and neck Cancer: A Case Report. Pembrolizumab诱导的头颈癌患者的主动脉炎：1例报告。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-01 DOI: 10.1097/CJI.0000000000000567

Erum Zaidi, Ningjing Li, Harshit Khosla, Syed H Jafri

引用次数: 0